| Filed On | Filing |
|---|---|
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
BERKELEY, Calif., November 5, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU) today reported financial results for the third quarter of 2026. |
| 06 Oct 2026 |
8-K: Costs Associated with Exit or Disposal Activities; Departure/Election of Directors or Officers; Compensation +2 more
— Company to evaluate strategic alternatives to maximize stockholder value — |
| 13 Aug 2026 | 10-Q |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overcome access barriers for patients with... |
| 27 Jul 2026 | SCHEDULE 13G |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 17, 2026, Caribou Biosciences, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). The final results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeti... |
| 11 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting |
| 05 Jun 2026 | DEFA14A |
| 07 May 2026 | 10-Q |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- |
| 01 May 2026 | DEFR14A |
| 24 Apr 2026 | ARS |
| 24 Apr 2026 | DEFA14A |
| 24 Apr 2026 | Proxy statement: annual meeting on June 17, 2026 |
| 10 Apr 2026 | PRE 14A |
| 31 Mar 2026 |
8-K: Regulation FD Disclosure; Other Events
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy |
| 05 Mar 2026 | S-8 |
| 05 Mar 2026 | 10-K |
| 05 Mar 2026 |
8-K: Results of Operations and Financial Condition
BERKELEY, Calif., March 5, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today reported financial results for fourth quarter and full year 202... |
Loading...